Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions. We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neff...
All content for FAACT's Roundtable is the property of FAACT's Roundtable Podcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions. We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neff...
Ep. 256: Tips for the Newly & Previously Diagnosed
FAACT's Roundtable
19 minutes
1 month ago
Ep. 256: Tips for the Newly & Previously Diagnosed
A new food allergy diagnosis—whether it’s your own or a loved one’s—can feel overwhelming. What many people need most in those early days are practical, real-world tips to make life feel manageable again. We’re joined by FAACT-recognized support group leader, physician's assistant, and advocate, Charity Luiskutty, who shares down-to-earth advice for those newly diagnosed, as well as smart reminders to help seasoned patients stay confident and on track. Resources to keep you in the know:...
FAACT's Roundtable
Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions. We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neff...
